[Correspondence] Rituximab and autologous stem-cell transplantation for high-risk diffuse large B-cell lymphoma – Authors' reply

The results from our randomised phase 3 trial1 showed that young patients, affected by high-risk diffuse large B-cell lymphoma (age-adjusted International Prognostic Index score of 2–3), who received abbreviated rituximab-dose-dense chemotherapy plus high dose therapy and autologous stem-cell transplantation compared with patients who received full course rituximab-dose-dense chemotherapy had an improvement in failure-free survival, but not in overall survival.

http://ift.tt/2fzC4oT